Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

HutchMed In-licenses Epigenetic Cancer Drug in $310 Million Deal

publication date: Aug 9, 2021

Shanghai's HutchMed announced a $310 million deal to acquire greater China rights to Epizyme's epigenetic treatment for niche cancers. Tazverik® is a methyltransferase inhibitor of EZH2 developed by Boston's Epizyme that is approved is the US to treat patients with epithelioid sarcoma or follicular lymphoma. HutchMed has not previously in-licensed any products. It will pay $25 million upfront and the rest in milestones. In addition, HutchMed will have a four-year warrant to acquire up to $65 million of Epizyme shares. More details....

Stock Symbols: (NSDQ/AIM: HCM; HKEX: 13) (NSDQ: EPZM)

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital